摘要
术后放射性碘(radioactive iodine,RAI)治疗分化型甲状腺癌(differentiated thyroid carcinoma,DTC)应根据患者的复发危险度分层实施,对于中高危患者的治疗疗效及安全性仍存在争议。相同危险度分层的DTC患者RAI治疗后的疗效及预后差异较大。已经公布的新的回顾性研究和前瞻性随机试验结果证明RAI治疗可降低中高危DTC患者的复发率和死亡率,同时也具备良好的安全性。笔者重点综述RAI治疗对中高危DTC患者治疗疗效的影响因素及不良反应的研究进展。
The treatment of differentiated thyroid carcinoma(DTC)by radioactive iodine(RAI)after surgery should be hierarchically implemented according to the degrees of recurrence risk.The efficacy and prognosis of RAI treatment in DTC patients with the same level of risk were quite different.New retrospective studies and prospective randomized trials have been published to demonstrate that RAI treatment can reduce recurrence and mortality among high-risk DTC patients,while also providing a good safety.This review focuses on the research progress of predictive factors and adverse reactions of RAI treatment in patients with moderate to high-risk DTC.
作者
温润泽
章斌
WEN Runze;ZHANG Bin(Department of Nuclear Medicine,The First Affiliated Hospital of Soochow University,Suzhou 215006,China)
出处
《标记免疫分析与临床》
CAS
2022年第12期2147-2153,共7页
Labeled Immunoassays and Clinical Medicine
关键词
分化型甲状腺癌
放射性碘治疗
治疗疗效
二次肿瘤
Differentiated thyroid carcinoma
Radioiodine therapy
Therapeutic effect
Peripheral blood image
Secondary tumor
